icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
3SkB6Qn2kGx7G44X